Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.

Michigan biotech follows 2021 collaboration in autoimmune disease with Amgen with its second tie-up, teaming up with Gilead in rheumatoid arthritis and systemic lupus erythematosus.

Expertise in dendritic cells could help generate new targets in cancer and autoimmune disease immunotherapy.

Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.